Cases of Chikungunya among children are being reported in recent days, Lady Ridgeway Hospital’s Consultant Paediatrician Dr. Deepal Perera said.Dr. Perera highlighted that the disease is spread by ...
Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different ...
Chikungunya infected children are being reported these days, said Dr. Deepal Perera, a specialist at the Lady Ridgeway ...
Chikungunya virus (CHIKV) is a mosquito-borne virus that has gained significant attention due to its widespread outbreaks and the severe health impacts it can cause. The disease, known as ...
Chikungunya virus (CHIKV) causes an acute febrile disease characterized by severe arthralgia in the small joints. This arthralgia is highly debilitating and can be chronic. CHIKV circulates ...
Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...
French-Austrian drugmaker Valneva's vaccine candidate against chikungunya, a mosquito-borne virus that causes occasional outbreaks across the world, showed promising results in a large new trial ...
The method involves using low-dose X-rays to render male mosquitoes unable to reproduce. Male mosquitoes don't bite and won’t have contact with people or spread disease.
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ ® ...